Clinical trial

Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756

NCT01278160

Study summary

ClinicalTrials.gov

Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention biphasic insulin aspart 30 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record metformin Normalized identity: metformin View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2011-01-01

PhasePHASE4

Conditions

Diabetesverified · MONDO: diabetes mellitus

Diabetes Mellitus, Type 2verified · MONDO: type 2 diabetes mellitus

Interventions

biphasic insulin aspart 30DRUG

metforminDRUG · verified · RxNorm: metformin

Sponsors & collaborators

Novo Nordisk A/Slead sponsor

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01278160 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.